Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613–22.
Article CAS PubMed Google Scholar
Chaemsaithong P, Pooh RK, Zheng M, Ma R, Chaiyasit N, Tokunaka M, et al. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population. Am J Obstet Gynecol. 2019;221:650.e1–650.e16.
O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. Am J Obstet Gynecol. 2016;214:103.e1–103.e12.
Yue C, Gao J, Zhang C, Ni Y, Ying C. Development and validation of a nomogram for the early prediction of preeclampsia in pregnant Chinese women. Hypertens Res. 2021;44:417–25.
Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet. 2019;393:1807–18.
Article CAS PubMed PubMed Central Google Scholar
Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012;206:58.e1–8.
Article CAS PubMed Google Scholar
Verlohren S, Perschel FH, Thilaganathan B, Dröge LA, Henrich W, Busjahn A, et al. Angiogenic markers and cardiovascular indices in the prediction of hypertensive disorders of pregnancy. Hypertension. 2017;69:1192–7.
Article CAS PubMed Google Scholar
Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005.
Article CAS PubMed Google Scholar
Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.
Article CAS PubMed Google Scholar
Cerdeira AS, O’Sullivan J, Ohuma EO, Harrington D, Szafranski P, Black R, et al. Randomized interventional study on prediction of preeclampsia/eclampsia in women with suspected preeclampsia: INSPIRE. Hypertension. 2019;74:983–90.
Article CAS PubMed Google Scholar
Zeisler H, Llurba E, Chantraine FJ, Vatish M, Staff AC, Sennström M, et al. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. Ultrasound Obstet Gynecol J Int Soc Ultrasound Obstet Gynecol. 2019;53:367–75.
Hund M, Allegranza D, Schoedl M, Dilba P, Verhagen-Kamerbeek W, Stepan H. Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol. BMC Pregnancy Childbirth. 2014;14:324.
Article PubMed PubMed Central Google Scholar
Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13–22.
Article CAS PubMed Google Scholar
Ohkuchi A, Masuyama H, Yamamoto T, Kikuchi T, Taguchi N, Wolf C, et al. Economic evaluation of the sFlt-1/PlGF ratio for the short-term prediction of preeclampsia in a Japanese cohort of the PROGNOSIS Asia study. Hypertens Res J Jpn Soc Hypertens. 2021;44:822–9.
Chen Y, Wang X, Hu W, Chen Y, Ning W, Lu S, et al. A risk model that combines MAP, PlGF, and PAPP-A in the first trimester of pregnancy to predict hypertensive disorders of pregnancy. J Hum Hypertens. 2022;36:184–91.
Article CAS PubMed Google Scholar
Liu L, Li H, Wang N, Song X, Zhao K, Zhang C. Assessment of plasma cell-free DNA and ST2 as parameters in gestational hypertension and preeclampsia. Hypertens Res. 2021;44:996–1001.
Article CAS PubMed Google Scholar
Zhou P, Luo X, Qi H-B, Zong W-J, Zhang H, Liu D-D, et al. The expression of pentraxin 3 and tumor necrosis factor-alpha is increased in preeclamptic placental tissue and maternal serum. Inflamm Res. 2012;61:1005–12.
Article CAS PubMed Google Scholar
Colmenares-Mejía CC, Quintero-Lesmes DC, Bautista-Niño PK, Guio Mahecha E, Beltrán Avendaño M, Díaz Martínez LA, et al. Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study. Hypertens Res. 2020;43:884–91.
Araki Y, Yanagida M. Hypertensive disorders of pregnancy: strategy to develop clinical peptide biomarkers for more accurate evaluation of the pathophysiological status of this syndrome. Adv Clin Chem. 2020;94:1–30.
Article CAS PubMed Google Scholar
Wakabayashi I, Yanagida M, Araki Y. Associations of cardiovascular risk with circulating peptides related to hypertensive disorders of pregnancy. Hypertens Res. 2021;44:1641–51.
Article CAS PubMed Google Scholar
Takagi K, Nakamoto O, Watanabe K, Tanaka K, Matsubara K, Kawabata I, et al. A review of best practice guide 2021 for diagnosis and management of hypertensive disorders of pregnancy (HDP) - misc. - researchmap. Hypertens Res Pregnancy. 2022;10:57–73.
Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72:24–43.
Article CAS PubMed Google Scholar
Espinoza J, Vidaeff A, Pettker CM, Simhan H. ACOG Committee Opinion No. 743: low-dose aspirin use during pregnancy. Obstet Gynecol. 2018;132:e44–e52.
Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin use to prevent preeclampsia and related morbidity and mortality: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021;326:1192–206.
Magee LA, Khalil A, Kametas N, von Dadelszen P. Toward personalized management of chronic hypertension in pregnancy. Am J Obstet Gynecol. 2022;226:S1196–210.
Article CAS PubMed Google Scholar
Hirsch A, Rotem R, Ternovsky N, Hirsh Raccah B. Pravastatin and placental insufficiency associated disorders: a systematic review and meta-analysis. Front Pharm. 2022;13:1021548.
Döbert M, Varouxaki AN, Mu AC, Syngelaki A, Ciobanu A, Akolekar R, et al. Pravastatin versus placebo in pregnancies at high risk of term preeclampsia. Circulation. 2021;144:670–9.
Espinoza J, Vidaeff A, Pettker CM, Simhan H. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135:e237–e260.
American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: chronic hypertension in pregnancy. Obstet Gynecol. 2019;133:e26–e50.
Metoki H, Iwama N, Hamada H, Satoh M, Murakami T, Ishikuro M, et al. Hypertensive disorders of pregnancy: definition, management, and out-of-office blood pressure measurement. Hypertens Res. 2022;45:1298–309.
Article PubMed PubMed Central Google Scholar
Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481.
Nobles CJ, Mendola P, Mumford SL, Silver RM, Kim K, Andriessen VC, et al. Preconception blood pressure and its change into early pregnancy: early risk factors for preeclampsia and gestational. Hypertension. 2020;76:922–9.
Article CAS PubMed Google Scholar
Li N, An H, Li Z, Ye R, Zhang L, Li H, et al. Preconception blood pressure and risk of gestational hypertension and preeclampsia: a large cohort study in China. Hypertens Res. 2020;43:956–62.
Huai J, Lin L, Juan J, Chen J, Li B, Zhu Y, et al. Preventive effect of aspirin on preeclampsia in high‐risk pregnant women with stage 1 hypertension. J Clin Hypertens. 2021;23:1060–7.
Slade LJ, Mistry HD, Bone JN, Wilson M, Blackman M, Syeda N, et al. American College of Cardiology and American Heart Association blood pressure categories—a systematic review of the relationship with adverse pregnancy outcomes in the first half of pregnancy. Am J Obstet Gynecol. 2023;228:418–29.e34.
Suzuki H, Takagi K, Matsubara K, Mito A, Kawasaki K, Nanjo S, et al. Maternal and perinatal outcomes according to blood pressure levels for prehypertension: a review and meta-analysis. Hypertens Res Pregnancy. 2022;10:29–39.
Ueda A, Hasegawa M, Matsumura N, Sato H, Kosaka K, Abiko K, et al. Lower systolic blood pressure levels in early pregnancy are associated with a decreased risk of early-onset superimposed preeclampsia in women with chronic hypertension: a multicenter retrospective study. Hypertens Res. 2022;45:135–45.
Committee on Obstetric Practice. Committee Opinion No. 692: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol. 2017;129:e90–5.
Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet. 2019;394:1011–21.
Article CAS PubMed PubMed Central Google Scholar
Bone JN, Sandhu A, Abalos ED, Khalil A, Singer J, Prasad S, et al. Oral antihypertensives for nonsevere pregnancy hypertension: systematic review, network meta- and trial sequential analyses. Hypertension. 2022;79:614–28.
留言 (0)